Updated version 1 - The U.S. Food and Drug Administration (FDA) has approved Inovio's drug for treating a rare throat disease; the company's stock price surged.

Stock information has been added in the second paragraph; see details in the third paragraph.

Reuters, October 30 - The U.S. Food and Drug Administration (FDA) said on Friday that it has approved Inovio’s therapy INO.O for treating a rare respiratory disease, marking the company’s first approved product.

Inovio's stock price surged by 215% in after-hours trading.

Inovio’s therapy INO-3107 (brand name Voceryq) offers a new treatment option for patients with recurrent respiratory papillomatosis, a condition that causes growths in the airway and often requires repeated surgical intervention.

(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Due to possible inaccuracies in automated translations or the absence of required context, Reuters does not guarantee the accuracy of automated translation texts and provides them for reader convenience only. Reuters accepts no responsibility for any harm or loss caused by using the automated translation function.)